152 related articles for article (PubMed ID: 34319315)
1. Iridium(iii) complexes as mitochondrial topoisomerase inhibitors against cisplatin-resistant cancer cells.
He L; Xiong K; Wang L; Guan R; Chen Y; Ji L; Chao H
Chem Commun (Camb); 2021 Aug; 57(67):8308-8311. PubMed ID: 34319315
[TBL] [Abstract][Full Text] [Related]
2. A mitochondria-targeting dinuclear Ir-Ru complex as a synergistic photoactivated chemotherapy and photodynamic therapy agent against cisplatin-resistant tumour cells.
Zhang C; Guan R; Liao X; Ouyang C; Rees TW; Liu J; Chen Y; Ji L; Chao H
Chem Commun (Camb); 2019 Oct; 55(83):12547-12550. PubMed ID: 31576841
[TBL] [Abstract][Full Text] [Related]
3. Palladium(ii) complexes with thiosemicarbazones derived from pyrene as topoisomerase IB inhibitors.
Oliveira CG; Romero-Canelón I; Silva MM; Coverdale JPC; Maia PIS; Batista AA; Castelli S; Desideri A; Sadler PJ; Deflon VM
Dalton Trans; 2019 Nov; 48(44):16509-16517. PubMed ID: 31670343
[TBL] [Abstract][Full Text] [Related]
4. Adjusting the lipid-water distribution coefficient of iridium(III) complexes to enhance the cellular penetration and treatment efficacy to antagonize cisplatin resistance in cervical cancer.
Huang W; Chen Z; Hou L; Feng P; Li Y; Chen T
Dalton Trans; 2020 Aug; 49(33):11556-11564. PubMed ID: 32716436
[TBL] [Abstract][Full Text] [Related]
5. Fluorinated cyclometalated iridium(iii) complexes as mitochondria-targeted theranostic anticancer agents.
Ouyang M; Zeng L; Huang H; Jin C; Liu J; Chen Y; Ji L; Chao H
Dalton Trans; 2017 May; 46(20):6734-6744. PubMed ID: 28488721
[TBL] [Abstract][Full Text] [Related]
6. Mitochondria-targeted phosphorescent cyclometalated iridium(III) complexes: synthesis, characterization, and anticancer properties.
Li Y; Liu B; Xu CX; He L; Wan YC; Ji LN; Mao ZW
J Biol Inorg Chem; 2020 Jun; 25(4):597-607. PubMed ID: 32232583
[TBL] [Abstract][Full Text] [Related]
7. Significant effects of counteranions on the anticancer activity of iridium(iii) complexes.
Zhang H; Guo L; Tian Z; Tian M; Zhang S; Xu Z; Gong P; Zheng X; Zhao J; Liu Z
Chem Commun (Camb); 2018 Apr; 54(35):4421-4424. PubMed ID: 29648559
[TBL] [Abstract][Full Text] [Related]
8. Valproic Acid-Functionalized Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents.
Ye RR; Cao JJ; Tan CP; Ji LN; Mao ZW
Chemistry; 2017 Oct; 23(60):15166-15176. PubMed ID: 28833658
[TBL] [Abstract][Full Text] [Related]
9. Iridium(III) Complexes Targeting Apoptotic Cell Death in Cancer Cells.
Ma DL; Wu C; Wu KJ; Leung CH
Molecules; 2019 Jul; 24(15):. PubMed ID: 31357712
[TBL] [Abstract][Full Text] [Related]
10. Novel and Versatile Imine-N-Heterocyclic Carbene Half-Sandwich Iridium(III) Complexes as Lysosome-Targeted Anticancer Agents.
Yang Y; Guo L; Tian Z; Gong Y; Zheng H; Zhang S; Xu Z; Ge X; Liu Z
Inorg Chem; 2018 Sep; 57(17):11087-11098. PubMed ID: 30133276
[TBL] [Abstract][Full Text] [Related]
11. Anticancer and antibacterial activity in vitro evaluation of iridium(III) polypyridyl complexes.
Yi QY; Zhang WY; He M; Du F; Wang XZ; Wang YJ; Gu YY; Bai L; Liu YJ
J Biol Inorg Chem; 2019 Mar; 24(2):151-169. PubMed ID: 30564887
[TBL] [Abstract][Full Text] [Related]
12. Highly potent half-sandwich iridium and ruthenium complexes as lysosome-targeted imaging and anticancer agents.
Li J; Tian Z; Xu Z; Zhang S; Feng Y; Zhang L; Liu Z
Dalton Trans; 2018 Nov; 47(44):15772-15782. PubMed ID: 30357192
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and topoisomerases inhibitory activity of heteroaromatic chalcones.
Jeon KH; Yu HB; Kwak SY; Kwon Y; Na Y
Bioorg Med Chem; 2016 Nov; 24(22):5921-5928. PubMed ID: 27707625
[TBL] [Abstract][Full Text] [Related]
14. Cyclometalated iridium(iii) complexes for mitochondria-targeted combined chemo-photodynamic therapy.
Qin WW; Pan ZY; Cai DH; Li Y; He L
Dalton Trans; 2020 Mar; 49(11):3562-3569. PubMed ID: 32123890
[TBL] [Abstract][Full Text] [Related]
15. A mitochondria-targeting hetero-binuclear Ir(iii)-Pt(ii) complex induces necrosis in cisplatin-resistant tumor cells.
Ouyang C; Chen L; Rees TW; Chen Y; Liu J; Ji L; Long J; Chao H
Chem Commun (Camb); 2018 Jun; 54(49):6268-6271. PubMed ID: 29850704
[TBL] [Abstract][Full Text] [Related]
16. Ester-Modified Cyclometalated Iridium(III) Complexes as Mitochondria-Targeting Anticancer Agents.
Wang FX; Chen MH; Hu XY; Ye RR; Tan CP; Ji LN; Mao ZW
Sci Rep; 2016 Dec; 6():38954. PubMed ID: 27958338
[TBL] [Abstract][Full Text] [Related]
17. Synthesis, characterization and anticancer activity in vitro and in vivo evaluation of an iridium (III) polypyridyl complex.
Yi QY; Wan D; Tang B; Wang YJ; Zhang WY; Du F; He M; Liu YJ
Eur J Med Chem; 2018 Feb; 145():338-349. PubMed ID: 29331805
[TBL] [Abstract][Full Text] [Related]
18. Triphenylamine-appended cyclometallated iridium(III) complexes: Preparation, photophysical properties and application in biology/luminescence imaging.
Liu X; Hao H; Ge X; He X; Liu Y; Wang Y; Wang H; Shao M; Jing Z; Tian L; Liu Z
J Inorg Biochem; 2019 Oct; 199():110757. PubMed ID: 31445461
[TBL] [Abstract][Full Text] [Related]
19. An iridium (III) complex as potent anticancer agent induces apoptosis and autophagy in B16 cells through inhibition of the AKT/mTOR pathway.
Tang B; Wan D; Wang YJ; Yi QY; Guo BH; Liu YJ
Eur J Med Chem; 2018 Feb; 145():302-314. PubMed ID: 29331753
[TBL] [Abstract][Full Text] [Related]
20. Discovery and Development of Topoisomerase Inhibitors as Anticancer Agents.
Kathiravan MK; Kale AN; Nilewar S
Mini Rev Med Chem; 2016; 16(15):1219-1229. PubMed ID: 27549098
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
